← FDA DRUG APPROVALS

FDA ANDA · ANDA064118

NYSTOP

nystatin

Sponsor: PADAGIS US

APPLICATION
ANDA064118
TYPE
ANDA
ORIGINAL APPROVAL
1996-08-16
LATEST ACTION
2002-11-13
ROUTE
TOPICAL
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

NYSTOPPrescription
NYSTATIN 100,000 UNITS/GM · POWDER · TOPICAL

Approval history

2002-11-13Manufacturing (CMC) · Supplement 11AP
2002-11-13Labeling · Supplement 12AP
2000-09-08Labeling · Supplement 10AP
1998-09-21Manufacturing (CMC) · Supplement 9AP
1998-09-21Manufacturing (CMC) · Supplement 8AP
1998-07-10Labeling · Supplement 5AP
1998-07-10Manufacturing (CMC) · Supplement 6AP
1998-07-10Manufacturing (CMC) · Supplement 4AP
1998-04-20Manufacturing (CMC) · Supplement 7AP
1997-07-30Manufacturing (CMC) · Supplement 3AP
1997-07-17Manufacturing (CMC) · Supplement 2AP
1997-02-10Manufacturing (CMC) · Supplement 1AP
1996-08-16OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →